Corporate News
Sep 28, 2026
REPROCELL and Polyphron Announce Collaboration to Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs
REPROCELL and Polyphron are partnering to enhance AI-driven human tissue research using StemRNA™ iPSCs, aiming to improve drug discovery and biological modeling.
Jul 27, 2026
REPROCELL Expands Clinical iPSC and Stem Cell Solutions in China Through Strategic Collaboration with WEIPU Biotechnology
REPROCELL partners with WEIPU Biotechnology to enhance cell therapy development in China, providing access to clinical-grade iPSC technologies and gene-editing services.
Jun 24, 2026
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)
REPROCELL has submitted a manufacturing and marketing approval application in Japan for Stemchymal®, a stem cell therapy aimed at treating spinocerebellar ataxia.
Jun 02, 2026
REPROCELL Receives Commercialization Award from Maryland Stem Cell Research Fund to Advance Universal, Hypoimmune iPSC Platforms
REPROCELL has received a Commercialization Award from the Maryland Stem Cell Research Fund to develop universal hypoimmune iPSC platforms for clinical applications.
Jun 01, 2026
REPROCELL Researchers Co-Author New Study Demonstrating the Potential of AI-Driven Drug Response Prediction for IBD Patients
REPROCELL researchers co-author a study showing how AI and multi-omics can enhance drug response predictions for inflammatory bowel disease patients.
Apr 09, 2026
REPROCELL USA Inaugurates GMP-Compliant Cell Culture Facility
REPROCELL USA has opened a new GMP-compliant cell culture facility to enhance regenerative medicine manufacturing and support global biopharmaceutical needs.
Mar 03, 2026
REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
REPROCELL launches GMP-compliant Master Cell Bank for clinical iPSCs, streamlining cell therapy development with an end-to-end integrated workflow from seed production to gene editing.
Mar 02, 2026
REPROCELL Expands Product Portfolio with Addition of BioThrust™ ComfyCell Incu Bioreactor Platform
REPROCELL expands its product portfolio with the BioThrust™ ComfyCell Incu bioreactor, enhancing capabilities in human cell culture and stem cell research.
Jan 28, 2026
REPROCELL Launches StemEdit: Clinical Gene Editing Services and New iPSC Lines Using AI-Designed Editing System
Press Release: commercial launch of StemEdit, REPROCELL's clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system.
Nov 07, 2025
REPROCELL Announces the Commercial Launch of its StemEdit Hypoimmune hiPSC Lines Generated with Advanced Gene Editing Innovations
REPROCELL announces the launch of new hypoimmune hiPSC lines using advanced gene-editing technologies, enhancing precision and efficiency in regenerative medicine and research applications.
Oct 22, 2025
REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)
REPROCELL USA receives Maryland Stem Cell Research Fund grant to develop GMP-grade CDMO and iMSC capabilities, enhancing their regenerative medicine and stem cell therapy manufacturing infrastructure.
Oct 21, 2025
REPROCELL Launches Next-Generation System for 3D Bioengineered Tissues
REPROCELL launches Alvetex® Advanced, enhancing 3D cell culture and bioengineered tissue models with improved flexibility and assay compatibility for pharmaceuticals, cosmetics, and medical device testing.
Oct 20, 2025
REPROCELL and Histocell Achieve GMP Certification for Manufacturing Process of Clinical-Grade iPSC Master and Working Cell Banks Using StemRNA™ Clinical iPSCs
REPROCELL and Histocell achieve GMP certification for clinical-grade iPSC manufacturing, advancing regenerative medicine and cell therapy production under EU regulations.
Aug 21, 2025
REPROCELL Launches ReproRegistry to Strengthen Access to Human Skin Samples for Research
REPROCELL launches ReproRegistry to improve research by providing better access to human skin samples for stem cell and drug discovery scientists.
Aug 20, 2025
REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy
REPROCELL launches NeoSight, a neoantigen detection service for personalized cancer immunotherapy, offering high-confidence data and applications like cancer vaccines and biomarker discovery.
Aug 13, 2025
REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model
REPROCELL and Durham University develop a reliable, iPSC-derived full-thickness human skin model for research and therapeutic applications, enhancing drug discovery and regenerative medicine.
Jul 22, 2025
REPROCELL Announces U.S. FDA Drug Master File Submittal for StemRNA™ Clinical iPSC Seed Clones
REPROCELL is pleased to announce the successful submittal of its StemRNA™ Clinical iPSC Seed Clones with the U.S. Food and Drug Administration (FDA) via a Type II Drug Master File (DMF).
Jul 02, 2025
Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration
Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.
May 05, 2025
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
Apr 25, 2025
Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment "Stemchymal®"
REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc., reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy "Stemchymal®". REPROCELL holds the exclusive commercialization license agreement for Stemchymal in Japan for the treatment of Spinocerebellar Ataxia (SCA).